Clinical Trials

Are you able to have a magnetic resonance imaging (MRI) scan and want to help people with heart failure? This study is developing new methods for imaging the heart and blood vessels using MRI to improve how healthcare providers diagnose people with heart failure. This study takes place in Maryland and Washington, DC.

Do you have a scheduled CT scan for heart disease? This study will look at different ways to take pictures of the heart and blood vessels using computed tomography (CT) that use less radiation than traditional scans. This study is located at the NIH Clinical Center in Bethesda, Maryland.

Are you an adult with obesity and at high risk of heart and blood vessel disease? This study is testing a new program to help people who have obesity stick to their healthy eating plan. Researchers from this study are developing a program that will predict when participants are most likely to stop making healthy food choices and will send messages to remind participants of their weight loss goals. To participate in this study, you must be 18 to 70 years old, have overweight or obesity, and be at high risk of heart and blood vessel diseases. This study takes place in Providence, Rhode Island.

Have you experienced a cardiac event in the past 6 months? This study assesses the efficacy of combining center-based and remote- or home-based cardiac rehabilitation sessions. Many patients who require cardiac rehabilitation, including those with angina myocardial infarction, heart failure, heart valve disease, and coronary heart (artery) disease, do not complete the necessary amount of rehabilitation sessions when done in a center-based environment. Researchers are investigating whether a combination approach will help. To participate in this study, you must be between 18 and 85 years old. This study takes place in Detroit, Michigan.

The purpose of this study is to determine the occurrence of scarring of the heart (cardiac fibrosis) and inflammation in those with perinatally acquired Human Immunodeficiency Virus (HIV) infection compared to people not infected with HIV. The information learned from this research may help the investigator to better understand the link between cardiac fibrosis and cardiac dysfunction and inflammation in those with perinatally acquired HIV infection compared to the uninfected.

The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to determine if acquired (partial) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) deficiency contributes substantially to the pathogenic mechanisms underlying Chronic Rhinosinusitis (CRS), creating a localized environment that impairs mucociliary clearance (MCC).

This project will determine the health impact of parenthood on people with cystic fibrosis (CF). The study team will use retrospective data to provide relatively immediate evidence on parenthood's effect on pulmonary health.

The purpose of this study is to look at lung ventilation in people with cystic fibrosis over time (1 year) using magnetic resonance imaging (MRI) with an inhaled contrast gas, and compare these measures to lung function assessed by spirometry and multiple breath nitrogen washout. This study also looks at how these measures change in response to a pulmonary exacerbation and treatment (if applicable). Over the span of a year, participants would be asked to complete 3-5 visits to the University of North Carolina at Chapel Hill (UNC). with each lasting up to 4 hours. If participants do not have a pulmonary exacerbation during the year they would be asked to complete 3 visits (one at enrollment, a second roughly 2 weeks later, and the third approximately a year later). If participants do experience a CF pulmonary exacerbation they would complete 5 visits (Visit 1, Visit 2, two exacerbation visits with one before treatment and the other after, and Visit 3 at one year after Visit 1). Only one exacerbation per participant will be tracked. Participants are eligible for this study if they are 18 years old or older, have Cystic Fibrosis (CF) with mild lung disease (FEV1 >/= 60%), and can undergo an MRI. There are no known benefits for participating in this study.